

Market Round-up

V23 – 26th October, 2018

General Market News:

- **AstraZeneca** and **MSD's Lynparza** shows significant results in ovarian cancer
[LINK](#)
- **Takeda** strikes US\$640m deal with **Enterome** for a global licence of EB8018, Enterome's lead bacterial inflammation blocker, targeting **Crohn's disease**
[LINK](#)
- **MSD's Keytruda** improved overall survival by up to 39% in first-line head and neck cancer, new results show.
[LINK](#)
- **Amgen** is lowering the price of its cholesterol medicine **Repatha** by almost 60% in the US, following a similar move from its competitor **Sanofi**, after both drugs failed to meet sales expectations.
[LINK](#)
- New pain drug from **Pfizer** and **Eli Lilly** treating osteoarthritis shows promise as opioid alternative
[LINK](#)
- Shire opens \$1.2bn, six-years-in-the-making facility in Georgia which will increase the company's plasma manufacturing capacity by one third.
[LINK](#)
- **Novartis** will acquire **Endocyte** for \$2.1bn, with the core of the deal centering on the Endocyte's experimental therapy for prostate cancer.
[LINK](#)
- **Novartis** announces Lancet publication of pioneering study in migraine prevention showing efficacy of **Aimovig®** where other treatments have failed
[LINK](#)
- **Lundbeck** experimental schizophrenia drug **Lu AF35700** fails Phase III trial
[LINK](#)

NCPE Drug Updates

- No updates this week.

Biologics / Biosimilars:

- **Amgen** launches **Humira** biosimilar, **Amgevita**, in markets across Europe
[LINK](#)
- **Orion** and **Amgen** to collaborate on the commercialisation of **AMGEVITA®** (biosimilar adalimumab) in Finland
[LINK](#)

Drug Approvals:

- FDA approves **Pfizer's PARP inhibitor** for metastatic breast cancer
[LINK](#)
- **Novartis** leukaemia drug **Kymriah** is approved in Switzerland
[LINK](#)

Brexit:

- Pharmacists in UK are calling for emergency powers to switch patients to new medications without consulting their GPs in the event of Brexit-induced drugs shortages.
[LINK](#)

Further Reading:

A possible "**Humirageddon**:" Perspectives on the EU biosimilar launch
[LINK](#)

Agility: How Pharma Can Be Bolder, Faster, Better *Whitepaper from eyeforpharma*
[LINK](#)
